Welcome to the Sensus Healthcare Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note that this event is being recorded. I would now like to turn the conference over to Kim Sutton-Golodetz with LHA Investor Relations. Please go ahead. Thank you. This is Kim Golodetz with LHA. Thank you all for participating in today's call. Joining me from Sensus Healthcare are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities law. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions, will, should or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, August 3, 2023. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms Form 10-K and Form 10-Q. During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release. With that said, I'd like to turn the call over to Joe Sardano. Joe? Thank you, Kim. Good afternoon, everyone. Our second quarter financial results showed improvement over the first quarter. During Q2, we shipped 13 systems, including 4 SRT systems outside the US and 6 SRT-100 Vision systems, up from 10 systems shipped during the first quarter of 2023, but down from 33 systems shipped in the prior year quarter. During the quarter, we did achieve a milestone. We have now shipped over 700 systems, 708 to be exact, in total, and are making progress as we drive towards 1,000 systems within the next couple of years. If you recall, we delivered the number 500 system during our 11th anniversary year. I made the statement during our then earnings call that we would achieve the next 500 units in half the time. So far, we are on track and we look forward to a better second half of 2023. For Q3, revenues were $4.5 million, an increase of 33% sequentially, but down from the $12.1 million a year ago. As discussed on last quarter's conference call, many of our customers depend on elective aesthetic procedures as a meaningful source of practice, revenue and profit, and we are hearing encouraging feedback that patient volumes and procedure mix are improving. As such, we continue to build inventory and prepay for components. We're confident that we are planning appropriately and we are receiving positive feedback from our customers that they are experiencing the return of their patients as volumes slowly grow back to previous levels. Speaking of volumes, our surveys of Medicare show that SRT is experiencing a 27% treatment growth rate year-over-year for the past 6 years. If this growth utilization rate continues at its current pace, SRT will soon become the treatment of choice for nonmelanoma skin cancer. Our confidence is high. We've been building inventory and prepaying for components. We expect to ship at least 60 SRT systems during 2023. Concurrently, we are working on programs that will address any remaining hesitancy for our prospects and put us back on a growth trajectory. Our advanced technology is expected to play a key role in our growth, with Sentinel IT front and center. This is our HIPAA-compliant software that stores patient data for multiple clinic purposes and will include artificial intelligence to allow customers to better manage their practices and data. Sentinel IT is expected to play a key role in our growth. We launched our Sentinel Sensus Cloud capabilities at the American Academy of Dermatology annual meeting this past March. This new feature of Sentinel is a cloud-based asset management, remote monitoring, and diagnostic platform, and is also now available on our lasers. The platform boasts continuous remote monitoring to track the status of a system from any web browser or iOS device. Continuous backups ensure that valuable information is safely stored in the cloud and allows providers with multiple locations or group practices to monitor their equipment remotely at all times. The Sensus Cloud system also allows providers to monitor any service issues, such as calibration, monitoring, voltage, and temperature, without having to send an engineer to the field. as you may expect, Sentinel IT allows us to track system use in real time, an important feature that may support new sales programs. We look forward to showcasing IT and our SRT products at local trade shows, as well as the American Society for Radiation Oncology, beginning October first. Although the sales cycle is longer for the hospital market, radiation oncology is a highly attractive opportunity as it gains interest in the skin cancer market. During the first quarter, we announced the sale of a system to a hospital in the Northeast, and we are engaged with several more hospital systems. We also introduced new and improved high-resolution ultrasound technology to provide a see and treat capability. This leads to great outcomes and patient reassurances because the physician can actually see the impact of each treatment on the lesion and lesion resolution after treatment. Our fair market value leasing program results in an ROI with only 2 to 2.5 patients treated a month. Interest in this program remains high, as evidenced by booth traffic at the conferences and trade shows we've been attending. Our customers are also inquiring about other types of sales programs, and we are actively looking at potential options. These activities are vital to our future. Not all dermatologists know about the attractiveness of SRT, as many still need to be educated. Given the higher reimbursement and favorable comparisons to most, overall, we've stepped up our marketing and education programs. While we've always had a presence at the key larger conferences, we're increasing our presence at smaller regional conferences. These events allow us to get closer to our customers without so many other companies competing for the attention. They also are more cost-effective. You can follow us on Facebook or Instagram to get a sense of how active we are. With that overview, overview, I'd like to turn the call over to Michael Sardano for a bit more color on our plans and our priorities. Michael? Thanks, Joe. Last quarter, I spoke about our efforts to open up new international territories, a demanding process requiring regulatory approvals and engaging the right distributors. In Q2, Sensus was pleased to announce our first system being sold into Ireland at Beacon Hospital in Dublin. Skin cancer is the most prominent cancer in Ireland, with more than 12,000 cases per year, so SRT should be in high demand. Sticking with that part of the world, Sensus also announced a new distribution partner in MIS Healthcare, a very large and well-respected company and Ireland. They bring a broad and growing network of relationships within the public and private healthcare sectors to support an effective market entry for Sensus. They also have a large service and maintenance operation, supported by a team of factory-trained engineers and application specialists. Additionally, in Q2, Sensus was excited to expand into the Central American territory with our first SRT system sold into Guatemala. With regard to the future, our plan is to expand our Latin American and Asian footprint as quickly as possible, with Brazil and Japan being longer-term goals as they are highly regulated. China remains our premier international market, with now more than 50 SRTs sold. With the pandemic lockdown lifted, we continue to see positive momentum and shipped another 2 SRT systems there during the quarter, for a total of 5 shipments to Asia so far this year. We expect that China will take delivery of more than 10 SRT systems throughout 2023, and we look forward to expanding further into the Asian territories with a specific target on Korea and Japan. With that, I'll turn the call over to Javier for a discussion of our financial results. Thanks, Michael. Good afternoon, everyone. As Joe mentioned, our revenues for the second quarter of 2023 were $4.5 million, an increase of 33% over the first quarter of 2023, and a decrease of 62.5% as compared with revenues of $12.1 million a year ago. The decrease versus the prior year was primarily due to a lower number of SRT units sold, as customers continued to defer purchases, as well as lower sales to a large customer. Gross profit for the second quarter of 2023 was $2.6 million, or 57.9% of revenues, compared with $8.3 million, or 68.3% of revenues for the second quarter of 2022. The decrease was primarily due to the lower number of units sold and higher costs charged by vendors in the 2023 quarter. Going forward, we anticipate gross margins to return to the mid-60% range as our sales continue to improve in the second half of the year. Selling and marketing expense for the second quarter of 2023 was $1.6 million, compared with $1.7 million for the second quarter of 2022. The slight decrease was attributable to lower marketing initiatives and commissions, partially offset by higher headcount costs. General and administrative expense for the second quarter of 2023 was $1.3 million, compared with $1.1 million for the second quarter of 2022. The increase was mostly due to higher professional fees, offset by a reduction in insurance expense. Research and development expense for the second quarter of 2023 was $0.8 million, unchanged from the same quarter last year. We expect R&D expense to remain at this same general level for the rest of the year. Other income of $0.2 million for the second quarter of 2023 was related to interest income. Net loss for the second quarter of 2023 was $0.4 million, or $0.02 per share, this compares with a net income of $3.5 million, or $0.21 per diluted share for the second quarter of 2022. Adjusted EBITDA, which we define as earnings before interest, taxes, depreciation, amortization, and stock compensation expense, was negative $1 million for the second quarter of 2023, compared with positive $4.7 million for the second quarter of 2022. I'll briefly review our year-to-date financial results. Revenues for the first half of 2023 were $7.9 million, compared with $22.4 million for the first half of 2022, reflecting a lower number of SRT units sold. Gross profit was $4.2 million or 53.4% of revenue, compared with $15.4 million or 68.7% of revenue for the first half of 2022. The decrease was primarily driven by the lower number of units sold and higher costs charged by vendors in the first half of 2023. Selling and marketing expense was $3.7 million for the first half of 2023, compared with $2.9 million for the first half of 2022. The increase was primarily attributable to higher trade show expense at a head count cost, partially offset by lower commissions. General and administrative expense was $2.9 million for the first half of 2023, compared with $2.4 million for the first half of 2022. The increase was primarily due to higher professional fees, offset by a reduction in insurance expense. Research and development expense was $1.9 million for the first half of 2023, compared with $1.6 million for the first half of 2022. The increase was mostly due to expenses related to the development of a drug delivery system for aesthetic use. We expect to complete this project by the end of the year. Other income of $0.5 million for the first half of 2023 was related to interest income. Other income of $12.8 million for the first half of 2022 was related to the gain on the sale of a non-core asset. Net loss for the first half of 2023 was $2.3 million or $0.14 per share. This compares with net income of $19.6 million or $1.17 per diluted share for the first half of 2022. Net income for the 2022 period includes a $12.8 million gain on the sale of a non-core asset. Adjusted EBITDA for the first half of 2023 was negative $3.7 million, compared with a positive $21.5 million for the first half of 2022. Turning now to our balance sheet. Cash and cash equivalents as of June 30, 2023, were $20.1 million, down from $25.5 million as of December 31, 2022, and up from $19.3 million as of March 31, 2023. The company had no outstanding borrowings under its revolving line of credit as of June 30, 2023, or December 31, 2022. We continue to prepare for the growth we envision. Specifically, we are building finished goods inventory and prepaying for materials, in part to get ahead of any inflationary price increases. Inventory stood at $10.1 million at the end of 2Q, up from $6.3 million at the end of Q1, and up from $3.5 million as of December 31, 2022. Prepaid and other current assets were $8.1 million versus $10.7 million as of March 31, 2023, and $6.9 million as of December 31, 2022. Our cash spend is very focused and is intended to support our ability to achieve our long-term goals. Nevertheless, our balance sheet continues to position us well to take advantage of the compelling growth opportunities we may come across. As a final comment, please see the table in the news release we issued earlier today for our reconciliation of GAAP to non-GAAP financial measures. With that, I'll turn the call back over to Joe. Thanks, Javier and Michael. SRT treatments surpassed 480,000 in the last 2 years alone, and the ROI for our premium SRT system under our fair market value leasing program continues to be compelling. Interest in SRT remains high. We expect to ship at least 60 SRT systems during 2023 and return to profitability in the second half of the year. Clinical results in treating nonmelanoma skin cancer non-invasively are excellent, with published studies showing that SRT is as good or better than Mohs surgery. This should be reason enough to choose SRT. Add to the fact that Mohs procedures can leave scars and raise the risk of infection, and the fact that our reimbursement is so much higher than it was 2 years ago, while Mohs surgery reimbursement has come down, and SRT becomes the clear choice. We are very excited to be working on making this choice even easier. As a final topic, before we take your questions, I want to add that our new lasers have the Sentinel IT solution capabilities embedded in them, including all six of our Sensus-branded aesthetic smart lasers and our transdermal drug delivery system. This system will, for example, allow PRP to be applied to the scalp in a pain-free hair restoration experience. Posters have already been presented on the application for hyperhidrosis or overactive sweat glands. We expect this device to be cleared by the FDA by the end of the year. Our transdermal drug delivery system has drawn interest from many pharmaceutical companies looking to provide patients with a pain-free experience. We are still in the early stages of tapping the enormous market opportunity for SRT. Our systems are well positioned in a large and largely untapped market. They provide a compelling alternative to surgery for millions of patients, and arguably, the only solution to prevent the recurrence of keloids following surgical incision. As an overlay to all this, an estimated 1 in 5 Americans will develop skin cancer during their lifetime. This tells us that nearly 70 million people will have non-melanoma skin cancer. Clearly, there's a need for our SRT systems, both now and even more so in the future. We're confident that Sensus is positioned for success despite the challenges we faced in February. We have a great staff to drive growth and implement our strategies, which is why we have built inventory to meet the expected demand. Make no mistake about our enthusiasm and excitement for our technology and our future. Our technology treats skin cancer as well or better than surgery, while we treat keloids better than anything else. With those comments, I thank you for your time and attention. Now, operator, we're ready to take questions. We will now begin the question-and-answer session. To ask a question, you may press star, then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. The first question comes from Scott Henry with ROTH Capital. Please go ahead. Thank you, and good afternoon. Joe, some, some progress, certainly sequentially from first quarter to second quarter. Can you talk about how we should think about the cadence in third and fourth quarter? Sounds like you're looking for about 35-40 placements. How should we think about when they may fall? Yes, Scott, thanks for being on. As we've said from the first quarter earnings call, that we experienced some delays, and the first half would be tough, but we thought that the second half would be a lot better. How do we look at it? We really are looking at approximately 60-plus systems for the year. I would say that third quarter traditionally has been a low quarter for us, but I think it's still gonna be better than the second quarter. I think the fourth quarter, which traditionally has always been our best quarter, will continue to be the best quarter. I think between the two, sequentially, I think, again, third quarter better than the second quarter, fourth quarter, best of all. Okay. If I recall, you, you'd made some comments about being, you know, break even or profitable in the second half of the year. It, it sounds like the break-even's about 16 units, give or take. Do you feel comfortable you'll be profitable for the second half of the year? Or, you know, what kind of guidance would you like to give? Yeah, no, I, I'd like to, you know, tell everybody that we will be profitable in the second half of the year. I think that we've been saying that from the beginning, that profitability would return. Our number one objective is to be profitable for the entire year. If things come around the way I think they will, we'll definitely meet the profitability objective that we've had from day one. Okay. On the income statement, it looks like selling expenses were a little lower than I would've expected in second quarter, down sequentially from first quarter. Anything of note there? How should I think about it going forward? Is first quarter or is second quarter more representative? Obviously, they go up a little with volume. Hey, Scott, this is Javier. It's a blend. I mean, in Q1, we had major trade show expenses that went through. In Q2, compared to last year, we had lower sales compared to last year, so we had lower commissions. You cannot take one of them as a, you know, example. It's basically a blend. You have to see the year-to-date. Okay, that's helpful. Final question, Joe, you know, what are you hearing from your customers? Are you seeing the shift in medical from aesthetic procedures, and are they okay with the higher, you know, finance rates given the current interest environment? Just kind of your color on the customer out. Well, the good thing, Scott, is that we're hearing from our customers that their customers are coming back. They're seeing a slight gain in the services from the aesthetic side, which again, puts cash in their pockets. We're excited for that part. It's also helping them focus on what SRT can do for them in their practice, with the fact that, you know, you have CPT codes, that's paid for by Medicare, this is a great opportunity for them to go after some revenue that maybe they didn't have before. I think that they're open, we've always said that we haven't lost any of the prospects. The prospect base continues to grow. A lot of the decisions were being delayed because of the fact of, you know, the impact that they had on the cash business. We're starting to hear some, some good rumblings from the, from the field. We're excited for them, that we seem to believe that the market is coming back based on their feedback. I think that's what we've been saying all along, that the second half will be a, a much better half as people get back to incorporating whatever economic situation they're experiencing as part of life and, and the way we move on. Okay, great. Thank you for taking the questions. Thank you, Scott. Thanks, Scott. Our next question comes from Anthony Vendetti with Maxim Group. Please go ahead. Thanks. Hi, Joe. Hey, Michael. How are you? How are you doing? Good and you? We're fine, Anthony. How are you? Good, thanks. On the, just shifting gears back to the transdermal infusion system that you've developed on your own now. Just where, where's the status with the 5 10(k) Maybe just an update on where that's at and what your expectations are in terms of the clearance there? Yeah. We've, we've gone through all of the, the, the regular testing through the government programs that have required it, those testings, those reports are, we're waiting for. We expect those reports to be incorporated into an FDA submission within the next 30 to 45 days. We expect FDA clearance before the end of the year. One of the things that we've added, which I think everybody would expect us to add, was the Sentinel capabilities into this program, so that the Sentinel Cloud and all of the opportunities with Sentinel are attached to this device as well. It clearly will give our customers the best options possible in providing this kind of a, a, drug delivery system, if you will. We're very, very excited for it. The, the addition of the Sentinel system, that the IT piece that you're putting with it, has, you know, the combination of the two is, is, is why it's taken a little bit longer, but you're expecting within the next 45 days to submit and then, approval by the end of the year. Is that right? Yeah, it hasn't. It, that wasn't what delayed it. It was the testing by the third-party agencies as designated by the FDA. You have to have those, and there, there's quite a line of people lining up to bring product to market through the FDA, and they've got a backlog. All of those testings have been completed, and the reports are being finalized, so that was the delay. When I say delay, it was maybe a 30-day delay overall. Okay. Then just as, just going back to the SRT systems and, you know, as, as, as I guess, the sales force has been speaking to, to clients, I know you're, you're, you're, you know, you, you've kept consistent with the, you know, 60 systems in total by, by 2023. As we enter the second half, just in conversations with dermatologists, what, what are you hearing in terms of their, their appetite for new systems as we move through the rest of this year? Are, are you hearing that that's, that's increasing just in general? You know, as, as we're dealing with, you know, higher interest rates and so forth, whether it's for the SRT or for other systems, is there a sense that dermatologists are, are, reticent or, or, or scaling back their purchases or, or, even, even leasing? Are things now back to what you would... I'm not going to say normal, but, but have, have returned in terms of what you would consider a normal appetite for, for new systems into their practice? I don't think that there's any question that they're coming back, and so we're getting feedback that things are gonna start moving in the second half. We're, we're seeing signs of that almost every day, so we're encouraged by talking to our customers. I think, you know, during these tough times, just like it was when we were going through COVID, for instance, it gave us an opportunity to get even closer to our customers, because they're always looking for solutions, and it gave us more opportunity to have dialogue with them. I think they knew that we were there for them during the tough times. We're there with them during the good times, just like we were during COVID. I think that the feedback that we've been getting has been very, very positive, and it's been very, very secure in how we're feeling towards the second half of the year. You know, we're, we're excited. Okay, great. And, and you did mention, I think, some, some sales in Asia, specifically China. I was wondering if you could talk about what you're seeing in that market, and then also just an update on Beacon Hospital in Ireland. Hey, Anthony, it's Mike. How are you? Good, Michael. How are you? Good, good. With regard to China, that seems to be very consistent. As I stated, the lockdowns are pretty much done, even in China. Benson has been, you know, our VP of international sales, has been in touch with our distributors in China and is a Chinese national himself, so he's very well connected in that area. We're seeing a lot of consistency, and like I said, there'll be over 10 systems sent to China throughout the entirety of 2023. With regard to Beacon Hospital, I went over there myself. I met with the contingency there, and it's in the dermatology and radiation oncology facility there, and they're very, very excited to have it. Beacon Hospital is probably the premier private hospital in Dublin. They have a high net worth individual client base, and they're very excited to start treating there. Good, good. Okay, great. You were there. What do you see as the opportunity, not just, not just in Ireland, with this as a sort of a premier hospital in Dublin, but what's the opportunity, do you believe, Michael, to use this sort of as like a platform hospital and scale the opportunity for Sensus throughout Europe? Yeah, let Anthony, let me answer that one, because I that's a very, very good question. If you I would invite anybody to go to the Beacon website and look up the hospital and look at the services that they provide. Like every other hospital, they list orthopedics, cancer care, heart. They have them all listed. One of the neat things that you see is dermatology. It's a collaboration between radiation oncology and dermatology to treat skin cancer. This being one of the premier private hospitals in the British Isles, they've deemed SRT from Sensus to be the best device to treat that that disease. I think that that's something that is a model that I think we're gonna start seeing in the U.S. If you go to most of the U.S. hospitals and look at their websites, whether private or for a nonprofit, they don't have dermatology listed in their, in their scope of services. All the other big ones are. I think you're gonna start seeing that coming about, just like we saw with Beacon Hospital. I think that's a good beacon for us to, to follow for the U.S.market and for beyond. It exists everywhere else in the world. I think it's gonna grow to the U.S. market as well. Good pun, Joe. Yes, very good. All right, great, thanks. I'll hop back in the queue. Appreciate it, guys. Thank you. Again, if you have a question, please press Star then One. Our next question comes from Alex Nowak with Craig-Hallum. Please go ahead. Hey, guys, this is Connor Chamberlain on for Alex. Hey, Connor. Thanks for taking the question. Hey, with the 2023 draft Physician Schedule coming out, have there been any changes to reimbursement for superficial radiation therapy? Nothing has been indicated. Michael. No, there was no mention of SRT in the Physician Fee Schedule. Got it. Got it. Okay. Which we didn't expect. Okay. Can you tell... Yep, yep. Can you walk us through how the sales team is adapting their process in this tough capital environment? I know you mentioned some lease programs, but can you just further expand on that a bit? Well, the, the lease program that we have, as we've been talking about for quite a while now, the, the fair market value lease, is something that's very encouraging for the customer to adapt. It's just another tool for the customer to, to gain access to our technology, and it's a very inexpensive way of doing it, much like a car lease, as, as I've described it, where the resid-- there's a, a hefty residual value, if you will, left on the equipment, so they're only paying for a certain portion of it. That will continue to grow, although most of our customers pay cash for the system. We're also coming up with some other, derivatives of opportunities to allow our customers to acquire our product in these tough times. You've got rentals, you've got shared, shared service programs. All of these things are being proposed to customers, and they're all evaluating those programs now. I think that we're going to see several of those contracts take effect between now and the end of the year, and I think it's gonna become popular. Got it. Got it. I got 1 more. How have your relationships been with your largest customers, in terms of their ordering patterns and demand? I know the 1st half of the year was difficult, but can you just further expand what you're seeing from your dermatology practices? Yep. They, they've been gone through the same thing that we've seen. I mean, it's the same market conditions for them as it is for us. Them being our best customer, I mean, it gives us opportunities to discuss together various opportunities to work closely together on how we can help drive the technology through the industry. That never ceases. I think that, you know, we've always said that we've got a great relationship there. They continue to push and try to grow their business, you know, they had the same, same problem as we did when we went through COVID. Now that we've gone through the first half of the year, I think they're gonna see a, a rejuvenation in their business in the second half, just like we are. Awesome. Awesome. All right, that's all I have, guys. Thanks. Let me bring one thing up, too, which I think is important for everybody to understand, which I mentioned during the introduction. We did a survey with Medicare, Medicaid, and found that there was a 27% compounded increase year-over-year for the last 6 years in treatments using SRT technology. That's a huge increase. That is massive. I don't want anybody to lose sight on the fact that more people are choosing to be treated with SRT versus any other option, versus surgery. One of the numbers that we mentioned, 480,000 people treated in the last 2 years. If that's gonna continue to grow at 27% year-over-year, which we feel it's gonna be, and maybe even accelerate from that, you can see where we're going to become the gold standard for treating skin cancer in the very near future. So that's important, is that the utilization of it, if you take the number of units that we have, we have now 708 systems worldwide, with about 600, 590 of those being in the U.S. You know, 480, that's, let's say it's an average of 240,000 patients a year. You can see how many patients each customer is treating every year, then you can calculate how much or how quickly their, their ROI is on the equipment. It, it's very easy to derive what kind of money they're making now that we have these significant, significant volumes of patients being treated. Our next question- Next question. Our next question comes from Ben Haynor with Alliance Global Partners. Please go ahead. Good afternoon, gentlemen. Thanks for taking the questions, and, you know, definitely appreciate the, the big picture commentary and not having to, to follow Joe's pun here. Just thinking about, you know, some, some of the, the, the things that you mentioned, the 480,000 treatments over the past couple of years. You know, how many treatments per case or per patient is, is... Does that factor in? You know, has that grown, shrunk? Is there any trend there? Well, what we're seeing, Ben, and I appreciate you being on, what we're seeing is between 14 and 16 fractions. So I guess you could say an average of 15 fractions per patient. Okay. - for the treatment of skin cancer. When we were talking about the number of, of, of, the numbers of 480,000, that's 480,000 skin cancers that are being treated. Lesions. Lesions, so it's not actual treatment. You times the number of treatments for those patients, 480,000 times an average of 15, gives you the number of treatments that are, that are taking place. Again, those treatments without anesthesia, because there is no pain, there is no cutting, no scarring, no bleeding, and best of all, you know, no scarring for the patient. We're-- That's what we're all excited about. I think that's, that's going great, and I think it'll continue to grow. I, I do appreciate the, the clarification there, 'cause I actually took it as 480,000 fractions, so, I would have been mistaken, I guess, there. Then on the, you know, getting to 1,000 systems, you know, obviously, you've made a, a big, a bigger push internationally. It's starting to bear fruit. You know, the, the next 300-ish systems, do you have a sense of how those will track in terms of the split, you know, domestic versus international, or any color that you might be able to share there? You know, I, I think that the international market is represented at about 5%- 7% of our overall revenue. Quite frankly, I think the biggest market is still in the U.S.. Sure. As we continue to grow, I think the biggest growth is still gonna be in the U.S. and the international market, in spite of growing and gaining more ground in different parts of the world. I still think it's gonna be between 5%, 7%, 8% of our overall revenue. It's still gonna come from the U.S.. Okay, got it. Then lastly, for me, on, on the Sentinel and the AI applications that you guys are building in, you know, I apologize if I, if I missed this, but, you know, what sort of functionality, functionality slash improvements slash, you know, applications does the, the AI that you're developing and putting in the, these, into Sentinel, enable? Well, I think, I think that we'll have to wait until we make the, the final introduction, which we expect to do by, AAD next March in San Diego. Mm-hmm. When you include AI, it gives you some unbelievable opportunities for the operator, for the patient, for the physician, all of the above, to benefit from that. It provides us with total EMR capabilities, electronic medical records, so that everything can be stored within the context of the product, as well as billing and, and all the billing and collections and all of those. I guess, you know, if I, if, if I had a dream, if I was to tell you what I think it's going to be, if you look at, at the Siri or any of these other things with some of the other programs. Mm-hmm. I could see us having a program where we can talk to the machine, and it'll give us exactly what we're looking for. Okay. stay tuned there, and, you know, it sounds like there's some exciting developments. Oh, yeah. It'll, it'll be fun. Good deal. Well, that's all I had, gentlemen. Thanks for taking the questions, and congrats on the sequential improvement. Thanks, Ben. Appreciate it. Thanks, Ben. This concludes our question and answer session. I would like to turn the conference back over to management for any closing remarks. Okay. Thank you. Thanks once again for your time this afternoon and for your interest in Sensus Healthcare, everybody. I'd like to mention that we'll be presenting at the Dawson James Small Cap Growth Conference on Thursday, October 12th, in Jupiter, Florida. In the coming weeks, we plan to hold a series of one-on-one virtual meetings, so please contact LHA if you'd like to get on the schedule. We'll speak with you again when we report third quarter financial results in early November. In the meantime, thank you all for joining us today. Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.